Fig. 1
From: Langerhans cell histiocytosis in adolescent patients: a single-centre retrospective study
Initial treatment in 36 adolescent LCH patients. A flow diagram demonstrates the initial therapeutic choices of LCH in adolescence, classified by system involvement. LCH: Langerhans cell histiocytosis; SS-s: one lesion within a single system or one organ; SS-p: pulmonary as the single system involvement; SS-m: multiple lesions within one single system; MS: multiple systems involved; VP: vindesine and prednisone; MA: methotrexate/cytarabine; AraC: cytarabine; 2-CdA: cladribine; ReA: reactivated